A patent is set to be granted by the Australian Patent Office for Amplicon AB's nicotine inhalation technology
Emplicure AB (publ) today announces that a patent is set to be granted by the Australian Patent Office for Amplicon's nicotine inhalation technology.
The Australian Patent Office has confirmed its intention to grant the patent application for inhalation of nicotine, application No 2017227071. This means the review and examination phase has passed and all terms are fulfilled. The patent is expected to be granted within the next months, and then into 2038.
"The granted patent solidifies the strength in Amplicon's proprietary bioceramic technology platforms and our potential for developing new unique nicotine products." says Tomas Hammargren, Chairman of the Board, Amplicon AB.
This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The informationen was submitted for publication, through the agency of the contact persons below, on March 30, 2022 at 08:45 CET.
Torbjörn W. Larsson
CFO, Investor Relations
Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via [email protected]
Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within bioceramic materials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subisidiary, Amplicon AB develops consumer products, with white tobacco-free nicotine pouches as the first product. Read more at www.emplicure.com
Emplicure utvecklar nya innovativa produkter baserat på kombinationen av redan godkända aktiva substanser och avancerad materialvetenskap inom biokeramer.
Få löpande information från Emplicure via e-post.